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Background: Subjects with breast cancer enrolled in trials may experience multiple events such as local recurrence,
distant recurrence or death. These events are not independent; the occurrence of one may increase the risk of
another, or prevent another from occurring. The most commonly used Cox proportional hazards (Cox-PH) model
ignores the relationships between events, resulting in a potential impact on the treatment effect and conclusions.
The use of statistical methods to analyze multiple time-to-event events has mainly been focused on superiority
trials. However, their application to non-inferiority trials is limited. We evaluate four statistical methods for multiple
time-to-event endpoints in the context of a non-inferiority trial.
Methods: Three methods for analyzing multiple events data, namely, i) the competing risks (CR) model, ii) the
marginal model, and iii) the frailty model were compared with the Cox-PH model using data from a previously-
reported non-inferiority trial comparing hypofractionated radiotherapy with conventional radiotherapy for the
prevention of local recurrence in patients with early stage breast cancer who had undergone breast conserving
surgery. These methods were also compared using two simulated examples, scenario A where the hazards for
distant recurrence and death were higher in the control group, and scenario B. where the hazards of distant
recurrence and death were higher in the experimental group. Both scenarios were designed to have a
non-inferiority margin of 1.50.
Results: In the breast cancer trial, the methods produced primary outcome results similar to those using the
Cox-PH model: namely, a local recurrence hazard ratio (HR) of 0.95 and a 95% confidence interval (CI) of 0.62 to
1.46. In Scenario A, non-inferiority was observed with the Cox-PH model (HR = 1.04; CI of 0.80 to 1.35), but not with
the CR model (HR = 1.37; CI of 1.06 to 1.79), and the average marginal and frailty model showed a positive effect of
the experimental treatment. The results in Scenario A contrasted with Scenario B with non-inferiority being
observed with the CR model (HR = 1.10; CI of 0.87 to 1.39), but not with the Cox-PH model (HR = 1.46; CI of 1.15 to
1.85), and the marginal and frailty model showed a negative effect of the experimental treatment.
Conclusion: When subjects are at risk for multiple events in non-inferiority trials, researchers need to consider using
the CR, marginal and frailty models in addition to the Cox-PH model in order to provide additional information in
describing the disease process and to assess the robustness of the results. In the presence of competing risks, the
Cox-PH model is appropriate for investigating the biologic effect of treatment, whereas the CR models yields the
actual effect of treatment in the study.
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Randomized controlled trials are considered to be the
gold standard for evaluating therapeutic interventions in
many different diseases including those in oncology.
Unlike studies in other diseases, cancer trials typically
follow subjects beyond the planned intervention, often
for many years. During this time, subjects may be at risk
for several events. For example, subjects in breast cancer
trials can experience local recurrence in the treated
breast, distant recurrence, death or a combination of
these. In most trials, only one of these events is consid-
ered the primary outcome and the others are secondary
outcomes. The occurrence of multiple events per subject
over a period of time is sometimes referred to as event
history data [1].
One of the most commonly used statistical approaches
for analyzing such data is the Cox proportional hazards
(Cox-PH) model, which models the time from ran-
domization to a specific event [2]. However, analyzing
each outcome separately using the Cox-PH model does
not make use of all the available information because it
fails to account for the plausible relationships or correla-
tions between events. For instance, it is possible that ex-
periencing one event increases the risk of experiencing
another event. Conversely, it is also possible that the
occurrence of one event may even prevent others from
occurring, a situation known as competing risks [3].
Standard survival analysis techniques have been shown
to bias results in such circumstances [4-6]. The effect
of treatment may differ depending on whether or not
intermediary events are incorporated into the analysis.
Several statistical methods exist to analyze event history
data. These include: the Cox-PH models [2], the compe-
ting risk (CR) model [7], the marginal model [8], and the
frailty model [9]. The majority of research has focused
on using these methods in the analysis of superiority
trials where the intervention is expected to be superior
to the standard treatment, but their application to non-
inferiority trials is lacking. Marginal and frailty models
are efficient methods of estimating treatment effect in
studies where patients have multiple events of the same
type, such as recurrence of asthma attacks. In addition,
they are used in studies where treatment can have an
effect on multiple events using the same biological
pathway. Research on the CR models in superiority
trials has shown the Kaplan-Meier approach over-
estimates the event rate in the presence of competing
risks. However, the relative treatment effect from the
CR model remains unchanged compared to the Cox-
PH model unless treatment affects the competing
event [10].
Non-inferiority randomized trials generally com-
pare the standard treatment with a new treatment
that is expected to be less toxic or less expensive orless invasive but “no worse” within a tolerance mar-
gin than the standard treatment in terms of clinical
outcome.
The purpose of this manuscript is to compare empi-
rically these different approaches in the analysis of a
non-inferiority trial in which a subject can experience
more than one type of outcome event. In addition, we
compare these methods using simulated examples of
trials. We first provide a brief overview of the methods,
and then apply them to a previously-reported random-
ized trial of hypofractionated radiotherapy in patients
with breast cancer [11,12], and to the simulated trial ex-
amples. For the purposes of this study, we will consider
the Cox-PH model for each type of event as the primary
analysis.
Methods
Cox proportional hazards (PH) model
The instantaneous rate of failure known as the hazard
rate is defined as the probability of failing in the next
small time interval, given that one has already survived
until the beginning of the interval [13]. The standard
Cox-PH model has become the most frequently used
method for modeling hazards and covariates. The model
does not make a distributional assumption about the
baseline hazard, and assumes that the covariate acts
multiplicatively on the hazard independent of time. The
model is given by the following:
λi t Xj Þ ¼ λ0 tð Þexp βXð Þð
where λi(t|X) is the hazard of subject i conditional on
covariate X at time t, λ0(t) is the baseline hazard at time
t, X is the covariate (e.g. 1 = experimental group, 0 =
control group), and β is the coefficient representing the
effect of treatment independent of time. In cancer trials,
the constant treatment effect is represented by the ratio
of hazards for the experimental group relative to the
control group, or hazard ratio (HR), given by exp(β).
Competing risks (CR) model
Kalbfleisch and Prentice developed the cumulative
incidence function (CIF) to analyze competing risk
data [14]. The CIF estimates the hazard of an event of
interest in the presence of other competing events,
known as hazard of the sub-distribution. The estima-
tion of the CIF is similar to that used by Kaplan-Meier;
however, the CIF does not censor subjects who expe-
rience a competing event and therefore does not re-
quire the assumption of independence between the
event of interest j and the competing events [4,15].
Fine and Gray [7] proposed a proportional hazards
model that models the effects of covariates on the ha-
zards of the CIF by distinguishing between competing
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Cox-PH model, the CR model is given by:
λsubij ðt Xj Þ ¼ λsub0j tð Þexp βsubj X
 
where λsubij t Xj Þð is the hazard of the sub-distribution
for cause j; λsub0j tð Þ is the baseline hazard of the sub-
distribution; and βsubj is the treatment effect of the sub-
distribution. This model reduces to the standard Cox-PH
model when competing risks are absent.
Marginal model
Wei, Lin and Weissfeld [8] proposed a marginal model
(WLW model) where a subject is assumed to be simultan-
eously at risk for all events, and is at risk for each event
until this event occurs [16]. The WLW model estimates
the treatment effect using independent Cox-PH models
for each event, and, therefore, the relationship structure
between event times does not need to be known [17,18].
For each event j for subject i, the model is given by
λijðt Xj Þ ¼ λ0j tð Þexp βjX
 
Stratification by event j allows for varying underlying
baseline hazards λ0j for each event. In addition, treatment
by event interactions allows for estimation of event-
specific treatment effects [18,19]. The WLW model also
estimates the ‘average effect’ of treatment β on all events
using a weighted average of β^j, which we will call the aver-
age WLW model. Dependencies between observed event
times are adjusted for by the use of a robust sandwich esti-
mate of the variance. In the presence of competing risks,
the WLW model models both the marginal hazard for
death and the cause-specific hazard for recurrences [19].
Frailty model
Frailty models are survival random effects models in
which a parameter for heterogeneity is incorporated into
the model. The model is given by:
λiðt Xj Þ ¼ λ0 tð Þexp βX þ γ i
 
where γi is the frailty parameter that can also be used to
model associations between event times [20]. A large par-
ameter value corresponds to a large correlation between
event times for a subject, and also describes the frailty or
excess risk within a subject [9,21,22]. This model assumes
that event times within a subject are independent given
the frailty parameter [20]. Similar to other random effects
model, this one also yields effects specific to the subjects
in the trial. Several published books provide excellent
reviews on frailty models [9,21,23].The hypofractionation trial
Between April 1993 and September 1996, 1234 patients
with early stage breast cancer who had undergone
breast conserving surgery were randomly allocated to
receive either 42.5 Gray of radiotherapy in 16 fractions
(the experimental arm) or 50 Gray in 25 fractions (the
standard arm) to the breast for the prevention of local
breast recurrence; details and long-term results are
described elsewhere [11,12]. The primary outcome of
local recurrence was compared was using a point-in
-time comparison of local recurrence failure probabil-
ities at five and 10 years [11,12].
For the purpose of this paper, HRs rather than point-
in-time failure probabilities will be used. The hypofrac-
tionation trial was designed with a control arm local
recurrence rate of 7% at 5 years. The non-inferiority
margin was set at 5% to tolerate an increase in local
recurrence to 12% in the experimental arm. This trans-
lates into a HR = ln(0.88)/ln(0.93) = 1.76. Additional
events of interest were distant recurrence, new primary
cancer and death. Because of the difficulty in differenti-
ating new primaries from distant recurrences, these will
be combined in the distant recurrence category. In
addition, we consider only the first occurrence of each
type of event.Simulated examples
Suppose that a randomized non-inferiority trial similar
to the Hypofractionation Trial were designed to demon-
strate that an experimental therapy E is as good as a
control therapy C for the prevention of local recurrence
in a subset of breast cancer patients. Assuming that the
rate of local recurrence at five years in the control arm
is 10.0%, and that the maximum tolerable rate of local
recurrence at five years in the experimental arm is
14.6% (HR = 1.50), then 1000 patients per treatment
arm would be required, giving 90% power and a one-
sided alpha of 0.025.
As with the Hypofractionation trial, we assume that
these patients will also be at risk for distant recurrence
and death. We simulated two possible outcome scenar-
ios (A and B) for this trial using a latent failure time ap-
proach. For each treatment group, data were generated
using two independent bivariate exponential models
based on the hazards in Table 1 [24]; one model for local
recurrence (l) and death (d1) with correlation of 0.2, and
the other for distant recurrence (m) and death (d2) with






if min l; d1;m; d2ð Þ ¼ d1
if min l; d1;m; d2ð Þ ¼ d2
if min l; d1;m; d2ð Þ ¼ l
if min l; d1;m; d2ð Þ ¼ m
8><
>:
Table 1 Hazards for simulated scenarios of non-inferiority
trials (LR = local recurrence, MR = distant recurrence,
DT = Death)
Scenario Outcome Hazard Rate Marginal
Experimental Control Hazard
Ratio
LR 0.02 0.02 1.00
A MR 0.02 0.03 0.67
DT 0.02 0.04 0.50
LR 0.03 0.02 1.50
B MR 0.03 0.02 1.50
DT 0.04 0.02 2.00
Table 2 Data structure for the WLW model for all possible
combinations of events (L = time to local recurrence, M =
time to distant recurrence, D = time to death, E = time at
end of follow-up, + = censoring indicator)
Event Stratum
Events Local Distant Death
L, M, D L M D
L, M L M E+
L, D L D+ D
M, D M+ M D
L L E+ E+
M M+ M E+
D D+ D+ D
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event, or the time of death that is linked to the first recur-
rence (local or distant). Independent censoring was gener-
ated so that approximately 40% of the observations were
censored. Survival times for event and censored observa-
tions were calculated for each subject by combining event
times and censoring times. Recurrences could occur only
prior do death (i.e. recurrence times were less than the
death time). Similarly, local recurrence could not occur
after distant recurrence. Censoring could occur prior to
any events occurring, or after recurrences have occurred.
Based on the standard error estimated from the Cox-PH
model using hypofractionation trial data, 1000 simulations
would produce an estimate to within at least 1.5 percent
of the true coefficient.Analysis
For the Cox-PH model, we structured the data in a “wide”
format (i.e. one record per subject). We fit Cox-PH
models for each event separately. For the local recurrence
model, death and distant recurrences are censored, and
for the distant recurrence model, death is treated as a
censored observation and local recurrence is ignored. Any
recurrence is ignored for the death model. Similarly, for
the CR approach, we fit Fine and Gray’s model [7] for each
event. Death and distant recurrences are treated as com-
peting events for the local recurrence model, and death is
treated similarly for the distant recurrence model. The
analysis for death is equivalent to the standard Cox-PH
model because death is always observable.
Data for the WLW model is set up in a “long format”
where every subject has three records, one for each
event, whether censored or observed. The events are
treated as independent strata in the model, and time is
expressed from randomization to each event. Table 2
shows the time and censoring mechanism for each event
given a subject’s event experience.The frailty model is fit using an extension of the Cox-
PH model that includes the frailty parameter that assumes
a gamma distribution because the events are assumed to
be positively correlated [25,26]. For this analysis, every
subject has at least one record representing vital status
(i.e. alive or dead) at the end of the study, and each recur-
rence is represented by an additional record.
For the simulation, the HRs and the standard errors of
the HRs were averaged on the log scale (1000 replica-
tions). All analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC) and R 2.13 (www.r-project.org).
Results
The hypofractionation trial
Figure 1 shows the results of the treatment effect using
each of the methods. The Cox-PH, CR and WLW models
all yield almost identical estimates for each of the events
of interest. The shorter experimental treatment does not
affect the occurrence of local recurrence, distant recur-
rence or death with HRs (95% CI) of 0.95 (0.62, 1.46), 1.12
(0.86, 1.43) and 0.97 (0.75, 1.24) respectively. Since the
upper 95% CI of the HR for local recurrence is less than
1.76, non-inferiority can be concluded. Moreover, the
frailty and WLW models also show that treatment does
not affect the risk of failure from all events combined.
Simulated examples
Results of scenario A (Figure 2), the Cox-PH and WLW
model yield an upper 95% CI of 1.35 for the HR for local
recurrence, thus suggesting that the experimental ther-
apy is non-inferior to the control. These models also
suggest a protective effect of experimental therapy on
distant recurrence and death. In contrast, the CR model
shows that the experimental therapy is not non-inferior
to the control with the upper confidence limit of 1.79
crossing the 1.50 margin. In addition, the CR model
yields a treatment effect of 0.96 (0.75, 1.21) for distant
recurrence. The frailty and average WLW model show
Figure 3 Forest plot showing the treatment effect in Scenario B
using each of the analysis methods (PH = proportional hazards,
CR = competing risks, WLW=Wei, Lin and Weissfeld, CI =
confidence interval). * average WLW model.
Figure 1 Forest plot showing the treatment effect in the
Hypofractionation Trial using each of the analysis methods (PH=
proportional hazards, CR = competing risks, WLW=Wei, Lin and
Weissfeld, CI = confidence interval). * average WLW model.
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all events combined.
The results of Scenario B (Figure 3) are opposite to that
of scenario A. In this case, the Cox-PH and WLW models
yield an upper 95% CI for the HR for local recurrence thatFigure 2 Forest plot showing the treatment effect in Scenario A
using each of the analysis methods (PH = proportional hazards,
CR = competing risks, WLW=Wei, Lin and Weissfeld, CI =
confidence interval). * average WLW model.is greater than the 1.50 margin. On the other hand, the
CR model shows that the experimental therapy is non-
inferior to the control with respect to local recurrence.
Moreover, the CR model shows that treatment has no ef-
fect on distant recurrence whereas the Cox-PH and WLW
models suggest a detrimental effect of the experimental
treatment on distant recurrence. The frailty and average
WLW model suggest that the experimental treatment is
harmful when considering all events together.
Discussion
In non-inferiority clinical trials of patients with breast
cancer, patients may be at risk of and may experience
multiple failure types. The occurrence of one of these
events may alter the probability of occurrence of other
events. Moreover, the influence of treatment may differ
depending on whether another event has occurred, thus
affecting the conclusions of the trial. This paper dis-
cusses, and applies four approaches of analyzing non-
inferiority trials with multiple events, by using data from
an existing trial in which subjects with breast cancer
could experience local recurrence, distant recurrence,
death, or a combination of these events. In addition, we
compared the methods using simulated examples of
non-inferiority trials.
The analysis of the Hypofractionation Trial showed that
treatment was not associated with increased risk of any of
the events of interest either individually or in combination.
The results for each event using the Cox-PH model and
the CR model are similar, suggesting that the impact of
competing risks in this data set is minimal. The treatment
estimates for each event from the WLW model are
Parpia et al. BMC Medical Research Methodology 2013, 13:44 Page 6 of 7
http://www.biomedcentral.com/1471-2288/13/44identical to those of the standard Cox-PH model since the
estimates of the regression coefficients are calculated using
equivalent methods. However, the adjustment of correl-
ation in the variance estimate of the WLW model leads to
slightly different confidence intervals when compared with
the Cox-PH model. The WLW model is also susceptible
to the competing risk problem since subjects are at risk
for events until they occur, but the model yields unbiased
estimates when treatment does not influence the compet-
ing events [27].
Scenarios A and B provide evidence that the presence of
multiple events could alter the conclusions of the trial
depending on the method of final analysis. The Cox-PH
and WLW local recurrence models ignore the hazards for
distant recurrence and death, thus resulting in different
conclusions for local recurrence when compared to with
CR model. Similarly, the Cox-PH and WLW distant recur-
rence models ignore the hazard for death. By ignoring the
competing risks, the Cox-PH and WLW methods model
the cause-specific hazard or the marginal failure times,
and the effect of treatment can be interpreted as the “pure
effect” or the biologic effect of treatment on the event of
interest [28]. This is the effect of treatment under the
assumption that the competing risk had not occurred,
which can be of interest to investigators.
Unlike the Cox-PH and WLW models, the CR model
does not censor patients who have had a distant recur-
rence or death, but rather assumes that these patients will
have a zero risk of local recurrence once distant recur-
rence or death is observed. Censoring assumes that the
patient is still at risk for local recurrence. Therefore, in the
CR model, the treatment group with higher relative haz-
ards of distant recurrence and death will have a relatively
lower hazard of local recurrence, and the HR for local re-
currence will favor this treatment group. This approach
models the hazard of the sub-distribution, and the effect
of treatment can be described as the “real effect” or the
actual effect seen in the data [28,29].
The CR model does provide additional information
about the treatment when competing events are
present. The Cox-PH model declares non-inferiority of
local recurrence, but the CR model shows that the
absolute effect of treatment is inferior in the study be-
cause the control group has a higher hazard of compet-
ing events (scenario A). However, in some situations
(scenario B),the results from the CR model should be
interpreted with caution since the CR model may show
that the experimental group is non-inferior to the
control for local recurrence, but at the expense of in-
creased distant recurrence or death, which are clinic-
ally worse outcomes. If this is a concern, one may opt
to design the trial using an outcome such as disease-
free survival which encompasses local and distant
recurrence. In addition, CR models have less powerthan the Cox-PH models to rule out the same non-
inferiority margin [30].
The average WLW and frailty models are useful in
investigating the overall effect of treatment for any event
accounting for the correlation between event times in
their respective ways. The main advantage of these
approaches is that they are efficient in their estimation
of regression coefficients due to their ability to use all
the data and to adjust for the association between event
times, thus increasing statistical power. However, their
use is limited when dealing with dissimilar types of
events with different clinical etiology such as local and
distant recurrence, because the approach does not
provide HRs of treatment and other factors in relation
to specific events but rather a combination of all events.
Moreover, these models do not correspond to the design
of the trial which is evaluating a local treatment and
based on rate of local recurrence.
The methods behave similarly in non-inferiority trials as
compared with superiority trials. As in superiority trials,
competing risks is an issue when treatment affects the
competing event. When the distribution of competing
events are similar in both treatment groups, the CR model
and the Cox-PH model yield similar results, and therefore,
the biologic effect and actual effect of treatment in the
study are similar. However, similar to superiority trials,
when treatment has a differential effect on competing
events, the results of the biologic and actual effect of treat-
ment can contradict each other.
A limitation of this study is that we compared analytic
techniques using a single non-inferiority trial. To over-
come this, we simulated examples to illustrate that the
choice of method may influence the conclusions. How-
ever, we simulated only two scenarios using the latent
failure time approach, thus limiting the generalizability
of the results. Secondly, we generated the data using a
latent failure time approach which is not without con-
troversy [31]. However, we did not use the model or its
assumptions in any of our analyses, and do not recom-
mend it for use for analysis. Lastly, we considered only
the most commonly used methods of analysis which are
readily available in current statistical software. Alterna-
tive options include jointly modeling all types of events
using a joint frailty model where each event has one
hazard function [32], or using a multivariate competing
risk frailty model [33]. However, such undertakings
would be computationally intensive and complex.
Conclusions
Our results show that the choice of event-specific models
did not affect the non-inferiority conclusion of the
Hypofractionation Trial. However, our examples showed
that the CR method did yield contrasting conclusions to
the Cox-PH and WLW models when competing events
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determined by the research question. The Cox-PH or the
WLW model can be used for analysis of non-inferiority
trials when the question relates to the biologic effect of
treatment. The CR model should also be used when com-
peting risks are present as it provides valuable information
on the actual effect of treatment in the study, especially
when treatment has an effect on the competing event.
Both models should be part of a comprehensive analysis.
The frailty and average WLW provide similar results of
the overall effect of treatment on all the events. When
subjects are at risk for multiple events in non-inferiority
trials, researchers should consider the use of the CR,
WLW and frailty models concurrent with the standard
Cox-PH model in order to provide additional information
in describing the disease process.
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